ArticleThorax2023
Super-responders to anti-IL-5/anti-IL-5R are characterised by high sputum eosinophil counts at baseline.
Article in Thorax, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Aberrant mucin expression and keratinization distinguishing severe from mild asthma revealed by interpretable machine learning.JCI insight · 2026Article
- Impact of sputum neutrophilia on the efficacy of biologics in severe asthma.Frontiers in allergy · 2026Article
- A novel method to assess airway eosinophilia using sputum plugs.ERJ open research · 2026Article
- The role of airway inflammation: effectiveness of mepolizumab in asthma with and without chronic rhinosinusitis and nasal polyps.Respiratory research & clinical practice · 2026Observational
- Mepolizumab Effectiveness in Severe Asthma With/Without Chronic Rhinosinusitis With Nasal Polyps: Real-World Pooled Analysis.Allergy · 2025Article
- Established and Emerging Asthma Biomarkers with a Focus on Biologic Trials: A Narrative Review.Journal of personalized medicine · 2025Review
- T1-T2 Interplay in the Complex Immune Landscape of Severe Asthma.Immunological reviews · 2025Review
- Biologics in severe asthma: a state-of-the-art review.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Article
- Article
- Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma.Frontiers in immunology · 2024Article
- The effect of benralizumab on inflammation in severe asthma: a real-life analysis.Therapeutic advances in respiratory diseaseObservational
- Review
- Mepolizumab for eosinophilic COPD with frequent exacerbations: single-centre real-world experience in a phenotype-directed approach.Therapeutic advances in respiratory diseaseArticle
- Biomarkers for selecting biologic therapies in asthma.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several clinical trials have demonstrated that anti-IL-5(R) biologics were able to improve lung function, asthma control and chronic oral corticosteroid exposure and reduce exacerbations among eosinophilic asthmatic patients. However, a certain variability in clinical responses to anti-IL-5(R) biologics was brought to light. Our study aimed at evaluating the role of baseline sputum eosinophils in identifying super-responders to mepolizumab and benralizumab. Our study reinforces the importance to examine sputum eosinophils in patients suffering from severe asthma before starting a biologic as it is associated with the intensity of response to mepolizumab and benralizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.